Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Oct 15;24(22):13472–13480. doi: 10.1111/jcmm.15977

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 The Authors. Journal of Cellular and Molecular Medicine published by Foundation for Cellular and Molecular Medicine and John Wiley & Sons Ltd.

This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

AML in Tgif1^−/− mice progressed earlier after chemotherapy than in Tgif1^+/+ AML mice. Sub‐lethally irradiated C57BL/6 mice were transplanted with spleen cells from Tgif1^+/+ or Tgif1^−/− mice with established MLL‐AF9‐induced AML, and two weeks following transplant, recipient mice were treated with doxorubicin for 3 d and cytarabine for 5 d by intraperitoneal injection. A, Percentage of GFP⁺ cells in peripheral blood were analysed using flow cytometry at day 0, day 10 and day18 after chemotherapy. B, Kaplan‐Meier analysis of survival of Tgif1^+/+ and Tgif1^−/− mice with AML after chemotherapy